Q&A Zealand Pharma 2019-05-29
Aktiesnakken
Bavarian Nordic
Shipping
Gubra
Ennogie
TESLA
NOVO
Biotek-snakken
Genmab
Amerikanske aktier
Vestas
Grønne Aktier
Smallcap og First North aktier
OLIE OG GAS
Hansa Biopharma
Pharma
Banker og Finans
BITCOIN
Embla Medical
ExpreS2ion
GN Store Nord
Medico
Laks
Zealand Pharma
AMBU
Chemometec
EL-BILER
Krypto
29/5 15:05 af Emmanuel Dulac |
At this stage in our development, we guide only on net operating expenses. We do not guide on revenue, but expect to receive some from new potential partnership agreements, and milestones from existing license agreements..
| |
29/5 15:04 af Helge Larsen/PI-redaktør |
What is the guidance for 2019? - and which important events do you expect this year?
| |
29/5 15:04 af Emmanuel Dulac |
It was a busy time to join Zealand Pharma! Yet it has also demonstrated to me the knowledge, capabilities, and reliability of the team.
| |
29/5 15:03 af Emmanuel Dulac |
We initiated three Phase 3 studies so far this year. Glepaglutide for SBS remains on track. We received a second set of Phase 3 results demonstrating dasiglucagon HypoPal as the fastest potential treatment of severe hypoglycemia. The first children with congenital hyperinsulinsm were dosed in the pivotal Phase 3 trial, with at least one already transitioning into the Phase 3 long-term study..
| |
29/5 15:02 af Emmanuel Dulac |
Zealand is off to a strong start in 2019. The agreement with Alexion signed in March has had big impact by validating our peptide platform and establishing partnership with the global leader in complement mediated diseases. The upfront payment also helped boost our overall cash position to about DKK 1.3b..
| |
29/5 15:01 af Emmanuel Dulac |
Thank you. I appreciate this opportunity to introduce myself to the Danish investment community and continue ongoing dialogue about Zealand Pharma..
| |
29/5 15:00 af Helge Larsen/PI-redaktør |
Can you please give us a short-term update on key figures and of important events for Q1 in 2019?
| |
29/5 15:00 af Helge Larsen/PI-redaktør |
Good afternoon, Emmanuel Dulac and welcome to your first Q&A with us here on ProInvestor.com. We are very happy to have you with us today - ready to answer a wide variety of questions from our investors.
| |
29/5 15:00 af Emmanuel Dulac |
Thank you for having me.
| |
29/5 14:59 af Emmanuel Dulac |
Yes, hello!
| |
29/5 14:58 af Helge Larsen/PI-redaktør |
Emmanuel Dulac, are you online?
| |
29/5 13:26 af Helge Larsen/PI-redaktør |
This session start at 16.
|